The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Increased Cardiovascular and Metabolic Morbidity in Patients With 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study
Abstract
CONTEXT: Congenital adrenal hyperplasia (CAH) is lethal in its most severe forms if not treated with glucocorticoids. However, glucocorticoids may increase the risk of cardiovascular and metabolic morbidity. OBJECTIVE: This study aimed to study cardiovascular and metabolic morbidity in CAH. DESIGN, SETTING, AND PARTICIPANTS: Patients with CAH due to 21-hydroxylase deficiency (n = 588; >80% with known CYP21A2 mutations) were compared with controls matched for sex, year, and place of birth (n = 58 800). Data were obtained by linking national population-based registers. Subgroup analyses were performed regarding sex, clinical severity (salt wasting, simple virilizing, nonclassic), CYP21A2 genotype (null, I2 splice, I172N, P30L), and stratified by the introduction of neonatal screening, age groups, and nonobesity. MAIN OUTCOME MEASURES: To study cardiovascular and metabolic morbidity in CAH. RESULTS: In CAH, both any cardiovascular and metabolic disorders (OR [odds ratio], 3.9; 95% CI [confidence interval], 3.1-5.0), and cardiovascular disease (OR, 2.7; 95% CI, 1.9-3.9) were increased. Separate analyses of the individual diseases showed higher frequencies in CAH of hypertension, hyperlipidemia, atrial fibrillation, venous thromboembolism, obesity, diabetes (mainly type 2), obstructive sleep disorder, thyrotoxicosis, and hypothyroidism. Similar results were seen in the stratified groups. On the subgroup level, females were generally more affected (especially I172N and the nonclassic group), as were males with the null genotype. CONCLUSIONS: CAH was associated with excess cardiovascular and metabolic morbidity but the mechanism is not certain as the glucocorticoids were not assessed. Hypothyroidism and obesity may be an effect of close observation. However, more severe conditions were presumably detected equally in patients and controls. Screening for diabetes and other metabolic disorders that increase cardiovascular risk is important.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Adjustments in glucocorticoid (and fludrocortisone) dose are usually necessary, especially in the third trimester (134), similar to pregnancies in women with primary adrenal insufficiency (668,669).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [668]
In the citing paper
“In a Swedish cohort of 588 CAH patients, there was a higher frequency of hypertension, hyperlipidemia, diabetes, and venous thromboembolism compared to controls.95”
From Congenital adrenal hyperplasia (2017) · cites this paper as [95]
In the citing paper
“A Swedish population-based study of 588 patients with CAH found an increased prevalence of obesity, type 2 diabetes mellitus, obstructive sleep apnoea, hypertension, elevated lipids, atrial fibrillation and venous thromboembolism compared with control individuals83.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [83]
Citations
Cites
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
White, P. C. (2000) · Endocrine Reviews · doi:10.1210/er.21.3.245 · Cited by 877
Congenital adrenal hyperplasia.
Merke, D. P., & Bornstein, S. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66736-0 · Cited by 628
Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients
Arlt, W., Willis, D. S., Wild, S. H., Krone, N., Doherty, E. J., Hahner, S., Han, T. S., Carroll, P. V., Conway, G. S., Rees, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0917 · Cited by 506
Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia
Finkielstain, G. P., Kim, M. S., Sinaii, N., Nishitani, M., Van Ryzin, C., Hill, S. C., Reynolds, J. C., Hanna, R. M., & Merke, D. P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2102 · Cited by 313
Grais, I. M., & Sowers, J. R. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.03.009 · Cited by 302
Hagenfeldt, K., Janson, P. O., Holmdahl, G., Falhammar, H., Filipsson, H., Frisen, L., Thoren, M., & Nordenskjold, A. (2008) · Human Reproduction · doi:10.1093/humrep/den118 · Cited by 205
Self-citation
Flagged first, then by citations
1 of the 36 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–203 of 203
Kouri, C., Sommer, G., Costa, F. C., de Miranda, M. C., du Toit, T., Heldt, K., Hess, M., Hirschberg, A. L., Markosyan, R. L., Neumann, U., et al. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag160
Self-citationThe evolution of new approaches to the treatment of congenital adrenal hyperplasia
Merke, D. P., & Auchus, R. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag033
Papadakis, J. L., Whitehead, J., Poquiz, J. L., Johnson, E. K., Finlayson, C. A., & Chen, D. (2026) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-026-10174-9
Metadata
- Authors
- Falhammar, H., Frisén, L., Hirschberg, A. L., Norrby, C., Almqvist, C., Nordenskjöld, A., & Nordenström, A.
- Affiliations
- Karolinska University Hospital (SE)
- Corresponding author
- Falhammar, Henrik
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-09
- Volume
- 100
- Issue
- 9
- Pages
- 3520-3528
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1890257176
- Cited by
- 204
- References
- 36
- Citations by year
- 2026: 11 · 2025: 21 · 2024: 17 · 2023: 20 · 2022: 24 · 2021: 20 · 2020: 20 · 2019: 19 · 2018: 21 · 2017: 19 · 2016: 8 · 2015: 3
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion)
- Open Archive (Karolinska Institutet) (submittedVersion)
- Funders
- Karolinska Institutet
- Stockholms Läns Landsting (340‐2013‐5867)
- Vetenskapsrådet (340–2013-5867)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- congenital adrenal hyperplasia, 21-hydroxylase deficiency, cardiovascular morbidity, glucocorticoid therapy, hypertension, hyperlipidemia, atrial fibrillation, venous thromboembolism, obesity, type 2 diabetes, obstructive sleep apnea, hypothyroidism, thyrotoxicosis, salt-wasting CAH, sex differences, newborn screening
- MeSH terms
- Adolescent, Adrenal Hyperplasia, Congenital, Adult, Aged, Aged, 80 and over, Cardiovascular Diseases, Child, Child, Preschool, Female, Genotype, Humans, Infant, Infant, Newborn, Male, Metabolic Diseases, Middle Aged, Risk, Steroid 21-Hydroxylase, Cohort Studies, Prevalence, Neonatal Screening, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
